OC
TARS icon

Oppenheimer & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

Oppenheimer & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Hold
4,150
– – ﹤0.01% 1540
2026
Q1 		$291K Hold
4,150
– – ﹤0.01% 1410
2025
Q4 		$340K Hold
4,150
– – ﹤0.01% 1237
2025
Q3 		$247K Buy
+4,150
New +$204K ﹤0.01% 1462
2025
Q2 		– Sell
-4,100
Closed -$211K – 1698
2025
Q1 		$211K Hold
4,100
– – ﹤0.01% 1433
2024
Q4 		$227K Buy
+4,100
New +$186K ﹤0.01% 1404
2024
Q1 		– Sell
-14,056
Closed -$285K – 1506
2023
Q4 		$285K Sell
14,056
-6,965
-33% -$116K 0.01% 1164
2023
Q3 		$374K Buy
+21,021
New +$372K 0.01% 1052

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Oppenheimer & Co's TARS Position: Q2 2026 in Review

Oppenheimer & Co held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 4,150 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Oppenheimer & Co first reported a position in TARS in Q3 2023 and has held it in 8 quarters since. The position peaked at $374K in Q3 2023. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Oppenheimer & Co held 4,150 shares of Tarsus Pharmaceuticals worth $261K as of Q2 2026.
  • Oppenheimer & Co left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1540 holding.
  • Oppenheimer & Co first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
  • Oppenheimer & Co's Tarsus Pharmaceuticals position peaked at $374K in Q3 2023.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.